"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...

Comorbidities, especially cardiovascular and autoimmune diseases, were frequent in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte ...

—If diagnosed sooner than later, NMOSD can be managed successfully. But once in remission, treatment decisions become more difficult. Are there biomarkers that might indicate who will fare better (or ...

Clinical Presentation Common symptoms of NMOSD result from damage to the optic nerve, spinal cord, and brainstem. These include optic neuritis with symptoms of loss or blurred vision in 1 or both eyes ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the results of the SAkuraSky Study (NCT02028884), a global phase III clinical study of satralizumab (development ...

The coronavirus disease 2019 (COVID-19) precipitates neurological symptoms for which the triggering of autoantibody diseases in the host could be a causative factor. Myelin Oligodendrocyte ...

Outcomes in acute optic neuritis tend to be worse at 6 months for men, patients who are older and those with poorer ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the results of the SAkuraStar Study (NCT02073279), a global phase III clinical study of satralizumab ...

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who ...

ROCHESTER, Minn. -- Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be ...